Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
MIGDAL HA'EMEQ, Israel, Feb. 03, 2016 -- Enzymotec Ltd. (NASDAQ:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2015 on Wednesday, February 17, 2016, before the market opens. Following the release, Dr. Ariel Katz, President and Chief Executive Officer, and Oren Bryan, Vice President and Chief Financial Officer, will host a conference call to review the financial results.
The conference call is scheduled to begin at 8:30 a.m. ET on Wednesday, February 17, 2016. Participants should dial (877) 359-9508 (United States) or (224) 357-2393 (International) with confirmation code 42574817 to access the live call. The call will also be broadcast live over the Internet, hosted in the Investors section of Enzymotec's website at http://edge.media-server.com/m/p/nznghg4j, and will be archived online within one hour of its completion through February 24, 2016.
About Enzymotec Ltd.
Enzymotec Ltd. is a leading global supplier of specialty lipid-based products and solutions. The Company develops, manufactures and markets innovative bio-active lipid ingredients, as well as final products, based on sophisticated processes and technologies. For more information, visit www.enzymotec.com.
CONTACT: The Ruth Group Tram Bui / Lee Roth (646) 536-7035/7012 [email protected] [email protected]
